Tibotec Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Leuven Belgium (1994)
Status: Acquired by Johnson and Johnson (2002)

Organization Overview

First Clinical Trial
2000
NCT00344422
First Marketed Drug
2006
darunavir (prezista)
First NDA Approval
2006
darunavir (prezista)
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BluKyne | Tibotec BVBA | Tibotec, Inc | Tibotec Pharmaceutical Limited | Tibotec Pharmaceuticals, Ireland | Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Active Ingredients

Marketed Drugs (2)

darunavir (prezista) (2006 NDA)

etravirine (intelence) (2008 NDA)

Drugs in Phase 4 Trials (9)

atazanavir (reyataz) (3 trials)

darunavir (prezista) (35 trials)

emtricitabine (emtriva) (3 trials)

etravirine (intelence) (22 trials)

lopinavir (Kaletra) (4 trials)

pravastatin (pravachol) (1 trial)

raltegravir (isentress) (5 trials)

ritonavir (Norvir) (30 trials)

tenofovir (viread) (5 trials)

Drugs in Phase 3 Trials (12)

capecitabine (xeloda) (1 trial)

daunorubicin (cerubidine) (1 trial)

doxorubicin (Doxil) (7 trials)

efavirenz (sustiva) (7 trials)

interferon alpha-2b (Intron-A) (12 trials)

ribavirin (virazole) (11 trials)

rilpivirine (edurant) (15 trials)

simeprevir (olysio) (30 trials)

telaprevir (incivek) (19 trials)

thalidomide (Thalomid) (1 trial)

urea (2 trials)

vincristine (oncovin) (2 trials)

Drugs in Phase 2 Trials (13)

abacavir (ziagen) (1 trial)

bedaquiline (sirturo) (6 trials)

bexarotene (targretin) (1 trial)

carboplatin (paraplatin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

enfuvirtide (fuzeon) (1 trial)

lamivudine (epivir) (1 trial)

maraviroc (selzentry) (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (1 trial)

tmc310911 (3 trials)

trastuzumab (herceptin) (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 1 Trials (27)

buprenorphine (1 trial)

ciprofloxacin (cipro) (1 trial)

cyclosporine (sandimmune) (2 trials)

dapivirine (2 trials)

digoxin (lanoxin) (1 trial)

docetaxel (taxotere) (1 trial)

erythromycin (ilosone) (1 trial)

escalitopram (Lexapro) (2 trials)

escitalopram (lexapro) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

fluticasone (cutivate) (1 trial)

fosamprenavir (lexiva) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

methadone (methadose) (2 trials)

moxifloxacin (avelox) (4 trials)

naloxone (narcan) (1 trial)

nevirapine (viramune) (1 trial)

norethindrone (1 trial)

omeprazole (prilosec) (1 trial)

pf-00258210 (1 trial)

rifampin (1 trial)

rosuvastatin (crestor) (1 trial)

tacrolimus (prograf) (2 trials)

tmc589337 (1 trial)

tmc589354 (1 trial)

tmc647055 (1 trial)

tmc649128 (2 trials)

Indications

Approved Indications


 

HIV

HIV Infections

Infections

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Breast Neoplasms (Phase 3)

Communicable Diseases (Phase 3)

Disease (Phase 1)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 2)

HIV Infections (Phase 4)

Hyperlipidemias (Phase 4)

Immunologic Deficiency Syndromes (Phase 3)

Infections (Phase 3)

Inflammation (Phase 1)

Insulin Resistance (Phase 1)

Kidney Diseases (Phase 1)

Liver Diseases (Phase 1)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Multiple Myeloma (Phase 3)

Mycoses (Phase 1)

Neoplasms, Plasma Cell (Phase 3)

Opioid-Related Disorders (Phase 1)

Tuberculosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 129
  • # of Trial APIs: 61